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Abstract: Twin reversed arterial perfusion (TRAP) sequence is a specific and severe complica-
tion of monochorionic multiple pregnancy, characterized by vascular anastomosis and partial or
complete lack of cardiac development in one twin. Despite its rarity, interest in the international
literature is rising, and we aimed to review its pathogenesis, prenatal diagnostic features and
treatment options. Due to the parasitic hemodynamic dependence of the acardiac twin on the
pump twin, the management of these pregnancies aims to maximize the pump twin’s chances of
survival. If treatment is needed, the best timing of intervention is still debated, although the latest
studies encourage intervention in the first trimester of pregnancy. As for the technique of choice
to interrupt the vascular supply to the acardiac twin, ultrasound-guided laser coagulation and
radiofrequency ablation of the intrafetal vessels are usually the preferred approaches.
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Introduction
Twin reversed arterial perfusion (TRAP) sequence, also known as acardiacmalformation,
is a unique complication of monochorionic multiple pregnancy in which one of the twins
lacks a complete cardiac structure (and so is called “acardiac”) while a morphologically
normal co-twin (called “pump twin”) supplies both circulations. Historically the first case
was described by Benedetti in 1533, and the first cases had been reported in the interna-
tional literature in the 1950s;1 thefirst description of prenatal diagnosis of an acardiac twin
was reported by Lehr and Dire in 1978.2 We aimed to review the pathogenesis, prenatal
diagnostic features and treatment options of this condition.
Epidemiology, Pathogenesis and Natural History
Traditionally, the incidence of this condition has been estimated at 1:35,000 preg-
nancies and 1:100 monozygotic twin pregnancies. However, van Gemert et al
assessed that, due to a better ultrasound diagnosis and the spread of assisted
reproductive technologies in recent years, TRAP incidence is growing towards
2.6% of monozygotic twins and 1 every 9,500 to 11,000 pregnancies.3
Regarding the pathogenesis of TRAP sequence, even though still debated, two
pathways have been historically proposed:4
Aberrant Placental Vascular Pattern in the Early Stages of
Monochorionic Placentation
An unbalanced blood flow between the twins is elicited. The pump twin prevails
thanks to its high-pressure flow, while the perfused twin receives a reversed
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deoxygenated blood flow, leading to compromised morpho-
genesis. The absence of the development of a functioning
heart leads to an acardiac twin that relies on the circulation
of pump twin in a parasitic fashion.
Primary Defect in Cardiac Embryogenesis
Secondary to a failure in heart formation, due to chromo-
some abnormality or environmental factors, the unique
perfusion support for the acardiac fetus is received through
anastomoses between the umbilical vessels.
Literature about the cytogenetic investigation of acar-
diac twins is limited. In some parasitic twins, investigators
found karyotypes that were different from those of the co-
twin.5 However, the etiology of cytogenetic discordancy in
TRAP twins remains unclear. Monochorionic twin preg-
nancies in humans are either monozygotic (as a result of
the late splitting of the embryo) or rarely dizygotic: the
development of acardiac fetuses in dizygotic twins has
been described in animals, through sharing of anastomoses
in fused placentae,6 and this might also happen in humans.
Altered embryogenetic pathways have been supposed to
trigger an impaired development of one of the twins and, in the
presence of vascular anastomoses, the vascular support depen-
dence of acardiac fetus on the predominant pump fetus.7,8
The acardiac twin is not viable, but during the intrau-
terine period is dangerous for the whole pregnancy. In fact,
the well-being of the pump twin can be compromised
through at least three mechanisms:9
(I) congestive heart failure and polyhydramnios of
the pump twin, caused by a risen cardiac work
due to the increased blood flow;
(II) preterm premature rupture of membranes
(pPROM), preterm labor and preterm delivery,
caused by uterine overdistension, since the acar-
diac twin is often bigger than pump twin and it
can reach a considerable size;
(III) hypoxia and intrauterine growth restriction of the
pump twin, caused by the deoxygenated blood
that comes back to the pump twin through vascu-
lar anastomosis.
For these reasons, the perinatal mortality rate for the pump
twin is up to 55%.9 Exceptionally, and for unknown rea-
sons, polyhydramnios can appear in the sac of the cardiac
twin.10 Some factors have been identified as markers of
a pump-twin poor prognosis:
● congestive heart failure displayed by hydrops or
polyhydramnios,
● delivery before 32 weeks,
● a big acardius size defined as an acardiac-to-pump
twin weight ratio>70%,
● discrepancy in pump/acardiac umbilical venous dia-
meter (UVD) ratio,
● the presence of a well-developed body and upper
extremities in the acardiac twin.
In particular, an acardiac-to-pump twin weight ratio>70%
has been associated with an incidence of 90% of preterm
delivery, 40% of polyhydramnios and 30% of congestive
heart failure.11 The pump/cardiac UVD ratio is a measure
of the excess pump cardiac output12 and can be used to
predict clinical outcomes of the risk prediction study per-
formed for this parameter.13 The haemodynamic basis of
the pump/cardiac UVD ratio rather than alternative non-
haemodynamic parameters (eg estimated weight or
abdominal circumference discrepancy) may prevent that
small acardiacs with very low vascular body resistances
leading to adverse outcome are missed.14
Ultrasound Diagnosis
The prenatal diagnosis of an acardiac twin should be consid-
ered when at ultrasound examination a monochorionic twin
pregnancy is displayed and one of the fetuses has evident
morphological abnormalities.15 The typical ultrasound fea-
tures are: gross differences in biometrical measurements of
twins, in particular regarding abdominal circumference;
absence of a morphologically normal heart in one twin asso-
ciated with several other malformations in head, trunk, upper
and lower extremities; presence of subcutaneous edema and
fluid collections in the anomalous twin (Figure 1). At times, an
irregular cardiac activity could be detected, as a result of
a rudimentary heart beating or a retrograde pulsation from
the pumping twin. A pathognomonic finding is the demonstra-
tion at color Doppler of a paradoxical circulation in the acar-
diac twin, with arterial blood flowing towards, rather than
away (Figure 2) and in a caudal-to-cranial course in the
abdominal aorta, which may be evident even during the first
trimester.16
Intrauterine death of an abnormal monochorionic twin
could resemble an acardius fetus, but maintained growth at
ultrasound follow-up shows the correct diagnosis; in these
cases, Doppler assessment of the monochorionic twin sus-
pected of being demised in utero should reveal the absence
of blood flow: persistent intrafetal blood flow signals
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should raise the suspicion of a TRAP sequence. Intra-
amniotic or placental tumors, as rare differential diag-
noses, can be ruled out by detection of the skeleton or
the umbilical cord attachment.11
Classification
Based on the morphology of the acardiac fetus, four dis-
tinct types have been described:1,17
● Acardius acephalus: is the most common type,
60–75% of cases, characterized by a good develop-
ment of pelvis and legs and an absence of cephalic
pole, thoracic organs and upper extremities.
● Acardius anceps: approximately 10% of cases; is the
most morphologically developed acardius, with
a recognizable body shape and extremities and
a rudimentary development of head and face.
● Acardius acormus: very rare, about 5% of cases;
characterized by the only presence of the cephalic
pole, while the body (if present) is a shriveled mass.
The head can be attached to the placenta either
directly or through the umbilical cord.
● Acardius amorphus: approximately 20% of cases;
absence of recognizable structures; the fetus appears
as a shapeless mass;
This classification allows a precise morphological description
but has no prognostic value and does not provide any infor-
mation about the best management option. It has been sug-
gested that the size of the acardiac twin plays a pivotal role in
the pathogenesis of complications that threaten the pump
twin. The exact weight of the acardiac twin cannot be calcu-
lated using the standard formulas based on ultrasound biome-
try (such as Hadlock’s), because of the usual lack of
anatomical structures; the following formula has been pro-
posed to estimate the weight of acardiac fetus: weight (g) =
1.2 × (longest length in cm)2 - (1.7 × longest length in cm).18
Since the measurement of the acardiac fetus may be
difficult to obtain, Wong et al focused on the use of the
abdominal circumference in evaluating the acardiac
fetus size and suggested a role of abdominal circumfer-
ence ratio as a prognostic factor.9 They proposed
a classification on the bases of prenatal ultrasound find-
ings as acardius size and signs of impaired cardiac
function of the pump twin; this classification may help
in identifying the most severe cases and those that need
prenatal interventions.
Acardiac anomalies are divided into:
● Type I: small or medium-sized acardiac twins, iden-
tified by an abdominal circumference ratio <50%.
● Type II: large acardiac twins, in which the abdominal
circumference ratio is ≥50%.
Each type can be further divided into a “subtype a”, if pump-
twin does not show signs of cardiovascular failure, or into
a “subtype b”, if these markers of failure are present.
Figure 1 Panoramic three-dimensional view of a twin reversed arterial perfusion
(TRAP) sequence at 15 weeks of gestation using Crystal Vue™ technique (Samsung
Healthcare, Italy). Arrow: acardiac twin. Dashed arrow: pump twin.
Figure 2 Color Doppler image of an acardiac twin at 14 weeks showing reverse
perfusion through the umbilical cord.
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Management and Treatment
The main goals in the management of the TRAP sequence
are preserving the survival of the pump twin and reaching
the term for delivery. According to the classification of
Wang et al discussed above, the finding of Type Ia acar-
diac fetus is quite reassuring about the prognosis of the
pump twin and allows a conservative management of
pregnancy through periodic ultrasound. This clinical con-
duct is associated with a good outcome in 88% of cases.19
In the presence of an acardius Type Ib, it is appropriate to
repeat ultrasound in order to identify a spontaneous reso-
lution or a worsening that requires an invasive treatment.
A Type IIa acardiac fetus can be large because of
subcutaneous edema or hydrops, and even if at the
moment of diagnosis the pump fetus shows no signs of
cardiac failure, the large size could threat the whole preg-
nancy due to an increased risk of preterm labor. In this
case, a prenatal treatment is required. The detection of
a Type IIb acardius requires a prompt intervention.
Timing of Intervention
Optimal timing of therapeutic intervention is still debated.
TRAP treatment has usually been performed at 16–18
weeks, hypothesizing that the risk of miscarriage could
be lower after the spontaneous obliteration of the celomic
cavity. However, the spontaneous loss rate of TRAP
pregnancies reported in the literature is between 35%
and 50%.12,15 In the last decade, the improvement of
ultrasound techniques has allowed the diagnosis of
TRAP sequence in the first trimester, raising some ques-
tions about the early management of this condition: is it
better to (a) wait for ultrasound signs of pump-twin
impairment, avoiding an early intervention, potentially
able to cause abortion and performing a preventive inter-
vention at 16–18 weeks, or (b) plan an intervention at
12 weeks, independently of ultrasound findings, in order
to preserve the pump twin from death between 12 and
16 weeks?
In 2010, a retrospective study of Lewi et al described
a pump-twin loss rate of 33% (8/24) in the time elapsed
from the first-trimester diagnosis and the elective interven-
tion at 16–18 weeks,20 showing an important disadvantage
of delayed procedures.
Pagani et al in a cohort study of 23 cases, 17 treated
with intervention and 6 managed conservatively, reported
an unexpected high spontaneous loss rate in the conserva-
tive treatment group (5/6, 83%). Data of treated cases in
this study were then combined with data from ten other
studies, and the analysis showed a significantly lower
adverse pregnancy outcome in the group in which the
treatment was undertaken before 16 weeks.21
Conversely, Roethlisberger et al in 2017 published
a retrospective analysis of TRAP sequences treated before
14+0 weeks, showing that fetal loss rate is significant in cases
treated in the first trimester. They also identified gestational
age at intervention and discordance between crown-rump
length (CRL) of the pump twin and upper pole-rump length
of the TRAP twin, measured as (CRL-URL)/CRL ratio and
URL/CRL ratio, as predictive factors of pregnancy outcome.22
A very recent work by Tavares de Sousa et al23 reports
a live birth rate of 92% at a median gestational age of 39+6
(interquartile range 37+1 to 41+2) weeks in 12 TRAP cases
treated before 14+3 weeks. These differences in outcome
may possibly be explained by variation in inclusion cri-
teria, operative technique, as well as gestational age and
fetal size even in the narrow interval between 11 and
15 weeks.
Hence, a multicenter, open-label, randomized controlled
trial currently ongoing (ClinicalTrails.gov:NCT02621645),
named the TRAP Intervention STudy (TRAPIST), compar-
ing treatment at 13–15 weeks vs treatment from 16 weeks,
is expected to define the optimal timing of treatment.
Treatment Techniques
Historically, initial therapeutic efforts in the setting of the
TRAP sequence aimed to relieve maternal or fetal compli-
cations. To counteract cardiovascular failure in the pump-
twin digoxin and other inotropic agents were used.24
Indomethacin has been employed to prevent premature
labor and to alleviate polyhydramnios.25 Other authors pro-
posed serial amniodrainage in order to reduce polyhydram-
nios and thus prevent preterm labor.26 After the clarification
of TRAP sequence pathophysiology,27 it has been estab-
lished that the causal treatment is to stop the blood supply to
the acardiac twin.
Robie et al reported in 1989 the first invasive interven-
tion: they planned a hysterotomy (sectio parva) at 22 weeks
with selective delivery of a 710 g acardiac twin; the healthy
pump twin was subsequently delivered at 33 weeks, weight-
ing 2130 g. This positive outcome animated other authors in
North America, and between 1989 and 1992, a total of seven
of these extremely invasive interventions were reported in
the literature. However, the technique showed important
maternal complications, including two cases of maternal
pulmonary edema deriving from aggressive tocolytic
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therapy, and adverse pregnancy outcomes, including three
cases of abruptio placentae.
In the following years, the acardius’s umbilical cord or
intra-abdominal vessels were identified as the principal
targets of new therapeutic techniques.
Cord Occlusion
In 1989 Hamada et al28 described the first case of percuta-
neous cord occlusion by coil embolization; another success-
ful case was described 2 years later by Porreco et al.29 Later,
other techniques targeting the umbilical cord were reported:
ligation under fetoscopy;30 hysterotomic incision, ultra-
sound-guided grasping, exteriorization and ligation of the
umbilical cord;31 vascular occlusion by thrombogenic
agents such alcohol-soaked suture material,32 fibrin, glu-
cose and enbucrilate gel.11
Both monopolar33,34 and bipolar35,36 thermocoagula-
tion techniques have also been used to interrupt cord
blood flow under ultrasound guidance. A supposed advan-
tage in using bipolar coagulation is energy passage only
between the two blades of the forceps, avoiding dispersion
through the umbilical cord, placenta and pump-twin
body.36 Nevertheless, this technique involves instruments
with large diameter, raising the risk of complications such
as pPROM. Furthermore, in different cases, the use of cord
ligation may be challenging: edematous cords (difficulty in
grasping umbilical cord), extremely short cords (accidental
placental damage), complicated access to the amniotic sac
of acardius (access through the pump-twin sac and disrup-
tion of dividing membrane).
In 1994, Ville et al reported laser coagulation of the
umbilical vessels during fetoscopy by neodymium yttrium
aluminium garnet (Nd:YAG).37 In 1998, Arias et al pub-
lished a systematic review including 22 cases of TRAP
sequence treated invasively. Among various techniques,
fetoscopic-assisted Nd:YAG laser cord occlusion appeared
the best treatment if performed at or after 24 weeks.38
Umbilical cord is often an insidious target for the risk
of damage to the pump twin. If the twin cords are too near,
cord occlusion can harm the pump twin’s cord. An intra-
vascular transfer of ablative material into the circulation of
the pump twin is possible if the artery within the acardiac
twin’s cord is erroneously inoculated. Furthermore, the
same acardius’s umbilical cord can be damaged causing
rupture or bleeding, because of its shortness, thinness and
anomalous structure. Hydropic acardiac fetuses often pre-
sent edematous cords and so laser or bipolar coagulation
may be challenging.
Using fetoscopy for cord ligation or laser coagulation
presents some drawbacks. A technical failure rate of 10%,
an increased risk of postoperative pPROM, intra-amniotic
infection and bleeding in pump twin have been reported as
complications. Endoscopic cord ligation needs the use of
general anesthesia and the insertion of at least two 12-gauge
trocars into the amniotic cavity. Likewise, laser coagulation
under endoscopy is a lengthy procedure that requires the
insertion of larger instruments into the amniotic cavity.38,39
In case of anterior placentas, fetoscopic access to the umbi-
lical cord may be hard and often additional interventions of
amnioinfusion or amniotomy must be performed to reach
more easily the acardiac twin’s umbilical cord. This leads to
a more invasive procedure, longer operative time and com-
plications as disruption of the intertwin membrane with
subsequent risk of pseudomonoamnionicity and entangle-
ment of the cord. Moreover, fetoscopy requires expensive
instrumentation, trained operators and is available in
a limited number of centers.
Intrafetal Ablation
The intrafetal approach has the goal of ablating the pelvic
vessels or the abdominal aorta of the acardiac twin, which
can be easily identified on color Doppler ultrasound. This
procedure is not influenced by placental location, umbili-
cal cord structure, amniotic fluid volume and position of
the acardius.
In 1987, Seed et al described the first but unsuccessful
attempt of intrafetal therapy: they repeatedly pierced the
pulsatile tissue within the acardiac twin in order to pro-
duce tamponade.40 Sepulveda in 1995 described the first
case of intrafetal ablation using a sclerosing agent (abso-
lute alcohol), explaining the new technique and the ratio-
nale for targeting the intra-abdominal rather than the
umbilical vessels.41 Various methods have been described
to perform intrafetal ablation: alcohol embolization, mono-
polar diathermy, laser and radiofrequency under ultra-
sound guide.
Alcohol embolization is the easier and most available
technique. It is an outpatient procedure that requires few
instruments: a 20- or 22-gauge spinal needle and a 5-mL
syringe loaded with absolute alcohol. Its main disadvan-
tage is the possibility of the transfer of the sclerosant agent
into the circulation of the pump twin and its subsequent
intrauterine death.
Recently, several energy sources have been used to
coagulate the intra-abdominal vessels and to obtain intra-
fetal ablation. The technique of monopolar diathermy
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requires an 18-gauge needle, a 1-mm diameter wire elec-
trode insulated with polytetrafluoroethylene along most of
its length except for 3 mm at the tip, a ground pad and
a standard monopolar diathermy generator.33 An alterna-
tive technique was described by Sepulveda et al in 2003
with the use of a simple wire.42 Monopolar diathermy is an
outpatient procedure, it can be performed under local
anesthesia and also in early pregnancy. The possible risk
of thermal injury to fetal and maternal tissues closer to the
inserted cannula is the principal complication.
An interesting procedure is an interstitial laser, exe-
cuted under local anaesthesia using an 18-gauge needle,
laser fibers and an Nd:YAG or diode laser generator.43,44
The skills required are similar to any other invasive need-
ling procedure: under ultrasound guidance, the needle is
inserted close to the target vessels into the abdomen or
pelvis of the acardiac twin; the laser fiber is then intro-
duced through the needle and its tip has to be seen slightly
beyond the needle. Then, pulses of laser energy are
applied, increasing power if necessary, until the occlusion
of the blood vessels is indicated by the hyperechogenicity
of the initial vascular area.
Interstitial laser and monopolar diathermy are similar
techniques, but the first one poses no risk of burns during
cauterization. Like in other interstitial procedures, the risk
of hemorrhage due to umbilical cord rupture is decreased
by the position of laser fiber in the body of the acardius;
this target also prevents unintended injury to the pump
twin or to the amniotic membrane. The use of a finer
gauge cannula than the one used for endoscopy or bipolar
diathermy theoretically diminishes the risk of membrane
rupture. Furthermore, interstitial laser can be used in early
gestation: nowadays TRAP sequences are often confirmed
in the first trimester and hence an early intervention could
reduce the occurrence of adverse outcomes in the pump
twin. The use of an operative microendoscopy before
16 weeks of gestation has been proposed, but the risk of
pPROM appears higher due to larger bore cannula
(2.7 mm maximal diameter).43
Radiofrequency ablation (RFA), the latest technique
described in the literature, employs a radiofrequency gen-
erator and a specific 3 mm/14-gauge needle device at the end
of which there are some tines that can be opened in a shape
similar to an umbrella.45 The RFA needle is positioned under
ultrasound guidance in the abdomen of the acardiac fetus; the
tines of the RFA device are deployed; radiofrequency energy
is released by the generator according to a specific calibra-
tion.When the device senses the increase in tissue impedance
as a result of necrosis, the power output stops. The effective-
ness of the procedure can be confirmed by Doppler ultra-
sound showing an absent flow to the acardius fetus.46 The
possibility of injuries to the co-twin or to surrounding tissues
is excluded since the energy is released from the radiofre-
quency device only after deployment into the target tissue.
Although the RFA device has the largest diameter of all
three methods, it appears to be relatively safe and effective
in the treatment of the TRAP sequence.
Technique Comparison
As discussed before, cord occlusion procedures have several
drawbacks if compared with intrafetal techniques. Tan and
Sepulveda in their review of literature compared 40 cases of
TRAP sequence treated by cord occlusion and 31 cases
treated by intrafetal ablation. The analysis results showed
a lower technical failure rate (13% vs 35%, p= 0.03), a lower
rate of premature delivery or pPROM before 32 weeks (23%
vs 58%, p= 0.003) and a higher rate of clinical success (77%
vs 50%, p= 0.02) using intrafetal ablation.11
Several experiences about the use of RFA for a selective
reduction in complex monochorionic pregnancies and, in
particular, for TRAP sequence treatment have been reported
in the last years. Cabassa et al published a case series and
reviewed the existing literature on the subject: 6 other studies
were included for a total of 88 pregnancies (monochorionic
twins or triplets with a monochorionic component). The
overall neonatal survival in the TRAP sequence treated by
RFA was 85% (75/88). Regarding pPROM, the most com-
mon post-procedural complication, not all studies reported
specific details and so the incidence of 22% (19/85) is
a rough estimate.46
In the North American Fetal Therapy network registry,
Lee et al found 98 TRAP cases treated by RFA, with a pump-
twin survival rate of 80%.47 Chaveeva and colleagues per-
formed a meta-analysis showing an overall survival rate of
80.8% for the pump twin after RFA treatment.48 Recently,
a study by Zhang et al listed 11 cases of RFA use in the TRAP
sequence. The overall survival rate of the pump twin was
70%.49
Since its first appearance in Jolly’s paper, the therapeu-
tic use of interstitial laser in the TRAP sequence has been
the subject of several studies. Pagani et al in 2013 per-
formed a retrospective cohort study and a review of litera-
ture about the TRAP sequence treated with intrafetal laser
therapy (ILF). A total of 51 pregnancies were included.
The overall neonatal survival was 80% (42/51); adverse
pregnancy outcome (intra-uterine death of pump twin or
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preterm birth before 37 weeks) was significantly lower
when treatment was undertaken before 16 weeks com-
pared with pregnancies treated at or after 16 weeks
(19%, 3/16 vs 66%, 23/35, respectively; p=0.0025).21
Chaveeva et al in 2014 added their case series and updated
the meta-analysis. The combined data included 104 twin
pregnancies treated by ILF. The overall survival rate was
76%.48
In recent years, endoscopic procedures have been
almost abandoned because of their invasiveness while
both RFA and intrafetal laser are the most commonly
used techniques appearing reliable and secure in the treat-
ment of TRAP sequence.
Pagani et al revising their case series noted that, even
though neonatal survival rate was comparable between the
intrafetal RFA and intrafetal laser techniques (85 vs 82%,
p=0.63), the incidence of pPROM before 32 weeks’ gesta-
tion was significantly higher with RFA (22 vs 7%,
p=0.045).21 In a multicenter study published by Scheier
et al, pump twins had a higher rate of intrauterine demise
if RFA treatment was performed at 15–19 weeks com-
pared to RFA treatment after 19 weeks (33.3 vs 10.7%).50
Chaveeva showed that the risk of death for the pump twin
using intrafetal laser is lower if the therapeutic interven-
tion is undertaken at 12–14 weeks than at later gestational
ages. In any case, a real comparison among RFA and IFL
has not been possible, since there is a lack of data about
RFA procedures performed before 15 weeks’ gestation.48
Challenges in Monoamniotic Twins
In approximately 5% of cases of TRAP sequence the
pregnancy is monoamniotic, ie the two fetuses are con-
tained within a single amniotic cavity. Often, the umbilical
cord of the acardiac twin is very short, and in this case
treatment options are not different from those in the more
common diamniotic pregnancies. However, if the cord of
the cardiac twin is long enough, it almost necessarily
becomes entangled with the umbilical cord of the pump
twin (Figure 3). If a standard intrafetal technique is
employed, the acardius’s cord may constrict that of the
pump twin, leading to its demise.51 In monoamniotic
pregnancies with entangled cords, therefore, devasculari-
zation of the acardiac twin is better achieved by coagula-
tion of the acardiac twin cord by means of fetoscopic laser
or ultrasound-guided bipolar coagulation, followed by
transection of the coagulated cord performed fetoscopi-
cally with a laser fiber or miniature scissors.51–53
Despite the rarity of this condition, the procedure
appears to be safe, with a 75% survival rate of the normal
twin.54
Conclusions
Management and treatment of TRAP sequence pose unre-
solved challenges, since both the technique of choice and the
optimal timing of intervention still have to be clarified. While
the current literature is rich in studies, their high heterogeneity
makes the comparisons prone to bias. If treatment is needed,
the best timing of intervention is still debated, although the
latest studies encourage intervention in the first trimester of
pregnancy. As for the technique of choice to interrupt the
vascular supply to the acardiac twin, ultrasound-guided laser
coagulation and radiofrequency ablation of the intrafetal ves-
sels are usually the preferred approaches.
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